control group:concurrent chemoradiotherapy

5 trials

Sponsors

The Second Affiliated Hospital of Xi'an Jiaotong University, Guizhou Cancer Hospital, Fudan University Shanghai Cancer Center, Department of radiotherapy, Changzhou Second People's Hospital, Cancer Center, Sun Yat-Sen University

Conditions

Cervical CancerEsophageal squamous cell carcinomaNasopharygneal carcinomalung cancer

Phase 1

A clinical study for Anlotinib combined with Platinum based dual drug concurrent radiotherapy for unresectable advanced non-small cell lung cancer

Active, not recruitingChiCTR1900020704

The Second Affiliated Hospital of Xi'an Jiaotong Universitylung cancer

Start: 2019-01-20Updated: 2019-01-28

Phase 2

A prospective, multicenter, randomized, controlled, phase II trial for comparing Camrelizumab combined radiotherapy and concurrent chemoradiotherapy in the treatment of unresectable locally advanced esophageal squamous cell carcinoma

Active, not recruitingChiCTR2000033308

Department of radiotherapy, Changzhou Second People's HospitalEsophageal squamous cell carcinoma

Start: 2020-06-30Updated: 2020-06-01

Phase 4

Randomized controlled clinical study for the efficacy and safety of neoadjuvant chemotherapy combined with concurrent chemoradiotherapy and concurrent chemoradiotherapy for locally advanced cervical cancer (lump=4cm)

Active, not recruitingChiCTR1900023257

Guizhou Cancer HospitalCervical Cancer

Start: 2019-06-01Updated: 2019-05-20

Unknown Phase

A randomized controlled study of concurrent chemoradiotherapy with or without consolidation chemotherapy for cervical cancer patients with lymph node metastasis after radical operation

Active, not recruitingChiCTR2000032834

Fudan University Shanghai Cancer CenterCervical Cancer

Start: 2020-08-16Updated: 2020-08-17

A multicenter, randomized, controlled, noninferior clinical study of reduced-concurrent chemotherapy for locally advanced nasopharyngeal carcinoma based on tumor response

RecruitingChiCTR2200056868

Cancer Center, Sun Yat-Sen UniversityNasopharygneal carcinoma

Start: 2021-03-01Updated: 2023-09-18